Prevention of non‐steroidal anti‐inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment
Open Access
- 19 April 2004
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 19 (10) , 1051-1061
Abstract
Summary: The incidence of non‐steroidal anti‐inflammatory drug‐related ulcer complications remains high despite the availability of potent anti‐ulcer drugs and selective cyclo‐oxygenase‐2 inhibitors. Non‐steroidal anti‐inflammatory drug‐related ulcer complications can be minimized by prospective assessment of patients’ baseline risk, rational choice and use of non‐steroidal anti‐inflammatory drugs, and selective use of co‐therapy strategies with gastroprotectives. Current recommendations regarding strategies using anti‐ulcer drugs and cyclo‐oxygenase‐2 inhibitors for prevention of clinical non‐steroidal anti‐inflammatory drug upper gastrointestinal events are largely derived from studies using surrogates such as endoscopic ulcers, erosions, and symptoms in low‐ to average‐risk patients. Conclusions based on surrogate and potentially manipulatable end‐points are increasingly suspect with regard to applicability to clinical situations. This article reviews the risks associated with non‐steroidal anti‐inflammatory drugs including aspirin and includes the effect of the patients’ baseline risk, and the confounding effects of Helicobacter pylori infection. In addition, uncertainties regarding the clinical efficacy of anti‐ulcer drugs and cyclo‐oxygenase‐2 inhibitors against non‐steroidal anti‐inflammatory drug‐related ulcer complications are put into perspective. We propose management strategies based on the risk category: low risk (absence of risk factors) (least ulcerogenic non‐steroidal anti‐inflammatory drug at lowest effective dose), moderate risk (one to two risk factors) (as above, plus an antisecretory agent or misoprostol or a cyclo‐oxygenase‐2 inhibitor), high risk (multiple risk factors or patients using concomitant low‐dose aspirin, steroids, or anticoagulants) (cyclo‐oxygenase‐2 inhibitor alone with steroids, plus misoprostol with warfarin, or plus a proton pump inhibitors or misoprostol with aspirin), and very high risk (history of ulcer complications) (avoid all non‐steroidal anti‐inflammatory drugs, if possible or a cyclo‐oxygenase‐2 plus a proton pump inhibitors and/or misoprostol). The presence of H. pylori infection increases the risk of upper gastrointestinal complications in non‐steroidal anti‐inflammatory drug users by two‐ to fourfold suggesting that all patients requiring regular non‐steroidal anti‐inflammatory drug therapy be tested for H. pylori.Keywords
This publication has 51 references indexed in Scilit:
- Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary SyndromesCirculation, 2003
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- How often are endoscopic ulcers in NSAID trials diagnosed as actual ulcers by experienced endoscopists?Gastroenterology, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Celecoxib Does Not Significantly Alter the Pharmacokinetics or Hypoprothrombinemic Effect of Warfarin in Healthy SubjectsThe Journal of Clinical Pharmacology, 2000
- Primary gastroduodenal prophylaxis with omeprazole for non‐steroidal anti‐inflammatory drug usersAlimentary Pharmacology & Therapeutics, 1998
- Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID useDigestive Diseases and Sciences, 1994
- Role of Helicobacter pylori Eradication in the Prevention of Peptic Ulcer Bleeding RelapseDigestion, 1994
- Treatment of Helicobacter pylori Reduces the Rate of Rebleeding in Peptic Ulcer DiseaseScandinavian Journal of Gastroenterology, 1993
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989